Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Lianhe Sowell International Group Ltd Ordinary Shares (LHSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: LHSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -22.76% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.99 - 8.18 | Updated Date 05/15/2025 |
52 Weeks Range 0.99 - 8.18 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Lianhe Sowell International Group Ltd Ordinary Shares
Company Overview
History and Background
Lianhe Sowell International Group Ltd. (formerly China SXT Pharmaceuticals, Inc.) was incorporated in the Cayman Islands in 2015. It operates as a holding company. The company has undergone a name change and has been involved in the development and marketing of pharmaceutical products. Specific founding year and detailed historical milestones are not readily available in public domain for this particular iteration of the company.
Core Business Areas
- Pharmaceutical Product Development and Sales: The company is primarily engaged in the research, development, manufacturing, and sale of pharmaceutical products, particularly focusing on cardiovascular and cerebrovascular diseases, and other therapeutic areas.
Leadership and Structure
Information on the current leadership team and detailed organizational structure is not readily available in public domain for Lianhe Sowell International Group Ltd.
Top Products and Market Share
Key Offerings
- Pharmaceutical Products: Lianhe Sowell International Group Ltd. develops and markets various pharmaceutical products. Specific details on flagship products, their market share, user numbers, or revenue contribution are not publicly disclosed. Competitors vary by specific drug and therapeutic area within the pharmaceutical industry.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory oversight, and intense competition. Growth is driven by an aging global population, increasing prevalence of chronic diseases, and advancements in medical science. The market for cardiovascular and cerebrovascular drugs is significant and competitive.
Positioning
Lianhe Sowell International Group Ltd. positions itself within the pharmaceutical sector with a focus on specific therapeutic areas. Its competitive advantages, if any, are not clearly defined in public disclosures. Key challenges include navigating regulatory hurdles and competing with larger, established pharmaceutical companies.
Total Addressable Market (TAM)
The TAM for the pharmaceutical industry, particularly for cardiovascular and cerebrovascular drugs, is substantial, measured in hundreds of billions of US dollars globally. Lianhe Sowell International Group Ltd.'s current market share is likely a very small fraction of this TAM due to its scale and product portfolio.
Upturn SWOT Analysis
Strengths
- Focus on specific therapeutic areas with significant patient populations.
- Potential for innovation in drug development.
Weaknesses
- Limited public information on specific products and market performance.
- Smaller market presence compared to major pharmaceutical players.
- Lack of readily available information on financial performance and leadership.
Opportunities
- Growing demand for cardiovascular and cerebrovascular treatments.
- Potential for strategic partnerships or acquisitions.
- Expansion into new geographic markets.
Threats
- Intense competition from established pharmaceutical companies.
- Stringent regulatory requirements and lengthy approval processes.
- Patent expirations and generic drug competition.
- Pricing pressures and reimbursement challenges.
Competitors and Market Share
Key Competitors
Competitive Landscape
Given the limited public information, a detailed competitive landscape analysis is not feasible.
Growth Trajectory and Initiatives
Historical Growth: Information on Lianhe Sowell International Group Ltd.'s historical growth is not publicly disclosed.
Future Projections: Future growth projections are not available due to a lack of public financial data and analyst coverage.
Recent Initiatives: Specific recent strategic initiatives undertaken by Lianhe Sowell International Group Ltd. are not publicly detailed.
Summary
Lianhe Sowell International Group Ltd. operates in the pharmaceutical sector, focusing on cardiovascular and cerebrovascular diseases. However, there is a significant lack of publicly available information regarding its history, leadership, products, financial performance, and market share. This makes it challenging to assess the company's strengths, weaknesses, or future prospects. Investors should exercise extreme caution due to the limited transparency.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Publicly available financial data aggregators (limited entries for this company)
- Company press releases (if any)
Disclaimers:
The information provided is based on limited publicly available data and may not be exhaustive or up-to-date. Investors should conduct their own thorough due diligence before making any investment decisions. This analysis is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lianhe Sowell International Group Ltd Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-04-03 | CEO & Director Mr. Yue Zhu | ||
Sector Technology | Industry Software - Infrastructure | Full time employees 30 | Website |
Full time employees 30 | Website | ||
Lianhe Sowell International Group Ltd, through its subsidiaries, provides machine vision products and solutions in China. The company offers industrial machine vision products; artificial intelligence products, such as face recognition and AI behavior analysis; intelligent weak current products, including building intelligence and intelligent transportation; and electronic customs clearance systems to manufacturing, transportation, security, and building management industries. It also provides nine-axis linkage spray painting robots for vehicle repair and maintenance industries. In addition, the company offers enterprise management services; develops software; and trades in electronic products. Lianhe Sowell International Group Ltd was incorporated in 2023 and is based in Shenzhen, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.